CUR 61414: inhibits the hedehog signaling pathway; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10392802 |
| CHEMBL ID | 480889 |
| SCHEMBL ID | 8256419 |
| MeSH ID | M0449944 |
| Synonym |
|---|
| n-((3s,5s)-1-(benzo[d][1,3]dioxol-5-ylmethyl)-5-(piperazine-1-carbonyl)pyrrolidin-3-yl)-n-(3-methoxybenzyl)-3,3-dimethylbutanamide |
| bdbm50249519 |
| CHEMBL480889 , |
| cur 61414 |
| 334998-36-6 |
| SCHEMBL8256419 |
| cur61414 |
| n-[(3s,5s)-1-(1,3-benzodioxol-5-ylmethyl)-5-(piperazine-1-carbonyl)pyrrolidin-3-yl]-n-[(3-methoxyphenyl)methyl]-3,3-dimethylbutanamide |
| DTXSID00439139 |
| g-856 |
| cur-61414 |
| AKOS030242346 |
| 809u4o7oqo , |
| unii-809u4o7oqo |
| g-024586 |
| CS-0064795 |
| HY-113965 |
| butanamide, n-((3s,5s)-1-(1,3-benzodioxol-5-ylmethyl)-5-(1-piperazinylcarbonyl)-3-pyrrolidinyl)-n-((3-methoxyphenyl)methyl)-3,3-dimethyl- |
| n-((3s,5s)-1-(1,3-benzodioxol-5-ylmethyl)-5-(piperazine-1-carbonyl)pyrrolidin-3-yl)-n-((3-methoxyphenyl)methyl)-3,3-dimethyl-butanamide |
| g-024856 |
| n-((3s,5s)-1-(1,3-benzodioxol-5-ylmethyl)-5-(1-piperazinylcarbonyl)-3-pyrrolidinyl)-n-((3-methoxyphenyl)methyl)-3,3-dimethylbutanamide |
| MS-30081 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sonic hedgehog protein | Homo sapiens (human) | IC50 (µMol) | 0.1000 | 0.0150 | 0.5930 | 1.7500 | AID351762 |
| Sonic hedgehog protein | Mus musculus (house mouse) | IC50 (µMol) | 0.2000 | 0.0030 | 1.1911 | 5.0000 | AID606346; AID606347 |
| Smoothened homolog | Homo sapiens (human) | IC50 (µMol) | 0.1400 | 0.0004 | 0.1640 | 1.5000 | AID661553 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID606350 | Inhibition of SHH pathway in mouse Shh Light2 cells at 0.3 uM after 40 hrs by Gli-dependent luciferase reporter gene assay | 2011 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12 | Synthesis and biological evaluation of desmethylveramiline, a micromolar Hedgehog inhibitor. |
| AID661558 | Displacement of BODIPY-labelled cyclopamine from human Smo receptor expressed in HEK293 cells after 2 hrs by fluorescence microscopy | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity. |
| AID606346 | Inhibition of SHH pathway in mouse Shh Light2 cells after 40 hrs by Gli-dependent luciferase reporter gene assay | 2011 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12 | Synthesis and biological evaluation of desmethylveramiline, a micromolar Hedgehog inhibitor. |
| AID606347 | Inhibition of N-terminal SHH activated pathway in mouse C3H10T1/2 cells assessed as SAG-induced cell differentiation by alkaline phosphatase assay | 2011 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12 | Synthesis and biological evaluation of desmethylveramiline, a micromolar Hedgehog inhibitor. |
| AID606348 | Inhibition of N-terminal SHH activated pathway in mouse C3H10T1/2 cells assessed as SAG-induced cell differentiation at 1 uM by alkaline phosphatase assay | 2011 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12 | Synthesis and biological evaluation of desmethylveramiline, a micromolar Hedgehog inhibitor. |
| AID606349 | Inhibition of N-terminal SHH activated pathway in mouse C3H10T1/2 cells assessed as SAG-induced cell differentiation at 10 uM by alkaline phosphatase assay | 2011 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12 | Synthesis and biological evaluation of desmethylveramiline, a micromolar Hedgehog inhibitor. |
| AID661482 | Antiproliferative activity against SAG-induced rat cerebellar granule cell precursors by [3H]-thymidine incorporation assay | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity. |
| AID661553 | Inhibition of Smo-mediated Hh signaling in human Shh-light2 cells by luciferase reporter gene assay | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity. |
| AID606352 | Inhibition of SHH pathway in mouse Shh Light2 cells at 10 uM after 40 hrs by Gli-dependent luciferase reporter gene assay | 2011 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12 | Synthesis and biological evaluation of desmethylveramiline, a micromolar Hedgehog inhibitor. |
| AID606351 | Inhibition of SHH pathway in mouse Shh Light2 cells at 3 uM after 40 hrs by Gli-dependent luciferase reporter gene assay | 2011 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12 | Synthesis and biological evaluation of desmethylveramiline, a micromolar Hedgehog inhibitor. |
| AID661552 | Inhibition of SAG-induced differentiation of mouse mesenchymal pluripotent C3H10T1/2 cells to alkaline phosphatase positive oeseoblasts after 6 hrs | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity. |
| AID351762 | Inhibition of lipid-modified (octylated) form of SHH expressed in mouse s12 cells by luciferase reporter gene assay | 2009 | Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13 | Hedgehog-Gli signaling pathway inhibitors as anticancer agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (7.69%) | 5.53% |
| Reviews | 5 (38.46%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (53.85%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||